JP2020526549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526549A5 JP2020526549A5 JP2020501256A JP2020501256A JP2020526549A5 JP 2020526549 A5 JP2020526549 A5 JP 2020526549A5 JP 2020501256 A JP2020501256 A JP 2020501256A JP 2020501256 A JP2020501256 A JP 2020501256A JP 2020526549 A5 JP2020526549 A5 JP 2020526549A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- triazole
- pyrrolo
- phenyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 C 1- C 6 alkoxy Chemical group 0.000 claims 106
- 150000001875 compounds Chemical class 0.000 claims 35
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 22
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 18
- 229910052799 carbon Inorganic materials 0.000 claims 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 15
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 13
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 13
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 12
- 229910052801 chlorine Inorganic materials 0.000 claims 12
- 229910052731 fluorine Inorganic materials 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 10
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- HVKYUNYBFWMKPT-UHFFFAOYSA-N FC1CC(N2N=C(N=C21)C(CC)=O)C1=CC=CC=C1 Chemical compound FC1CC(N2N=C(N=C21)C(CC)=O)C1=CC=CC=C1 HVKYUNYBFWMKPT-UHFFFAOYSA-N 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- ADFFEHJDGDXCFG-UWVGGRQHSA-N (5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=CN=C21)C2=CC=CC=C2 ADFFEHJDGDXCFG-UWVGGRQHSA-N 0.000 claims 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 3
- HKTIIUVJXGYOGD-UHFFFAOYSA-N OC(C(=O)C=1N=C2N(N=1)C(CC2F)C1=CC=CC=C1)(C)C Chemical compound OC(C(=O)C=1N=C2N(N=1)C(CC2F)C1=CC=CC=C1)(C)C HKTIIUVJXGYOGD-UHFFFAOYSA-N 0.000 claims 3
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 3
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- MMAQBOVBDLUDFG-UHFFFAOYSA-N 1-(4-phenyl-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazin-2-yl)propan-1-one Chemical compound CCC(=O)c1cc2C(OCCn2n1)c1ccccc1 MMAQBOVBDLUDFG-UHFFFAOYSA-N 0.000 claims 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 2
- JLUSKXSRUBDULB-UHFFFAOYSA-N CCC(=O)C1=NN2CCOC(C2=C1)C1=C(F)C=CC=C1 Chemical compound CCC(=O)C1=NN2CCOC(C2=C1)C1=C(F)C=CC=C1 JLUSKXSRUBDULB-UHFFFAOYSA-N 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 claims 2
- 125000004188 dichlorophenyl group Chemical group 0.000 claims 2
- 125000004212 difluorophenyl group Chemical group 0.000 claims 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- QAPYHKXOTXWXPZ-UHFFFAOYSA-N 1-(5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)propan-1-one Chemical compound CCC(=O)c1nc2CCC(c3ccccc3)n2n1 QAPYHKXOTXWXPZ-UHFFFAOYSA-N 0.000 claims 1
- DOJZSEYEQKWUSI-UHFFFAOYSA-N 1-methylcyclopropane-1-carbaldehyde Chemical compound O=CC1(C)CC1 DOJZSEYEQKWUSI-UHFFFAOYSA-N 0.000 claims 1
- ASISMDYYMIKZLM-STQMWFEESA-N 2-[1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-carbonyl]cyclopropyl]acetonitrile Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)C(=O)C1(CC#N)CC1)C1=CC=CC=C1 ASISMDYYMIKZLM-STQMWFEESA-N 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims 1
- TUQCZDPZDKQRTM-UHFFFAOYSA-N 3,3,3-trifluoro-1-(7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)-2-hydroxypropan-1-one Chemical compound OC(C(=O)c1nc2C(F)CC(c3ccccc3)n2n1)C(F)(F)F TUQCZDPZDKQRTM-UHFFFAOYSA-N 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- YPYQCUPKRSMMSN-UHFFFAOYSA-N C1(CC1)C(=O)C=1N=C2N(N=1)C(CC2)C1=C(C=CC=C1)F Chemical compound C1(CC1)C(=O)C=1N=C2N(N=1)C(CC2)C1=C(C=CC=C1)F YPYQCUPKRSMMSN-UHFFFAOYSA-N 0.000 claims 1
- AVFXGWVZFIBROG-UHFFFAOYSA-N CC(C(=O)C=1N=C2N(N=1)C(CC2F)C1=CC=CC=C1)(C)C Chemical compound CC(C(=O)C=1N=C2N(N=1)C(CC2F)C1=CC=CC=C1)(C)C AVFXGWVZFIBROG-UHFFFAOYSA-N 0.000 claims 1
- QRRBMFKBYJOWCZ-UHFFFAOYSA-N CCC(=O)C1=CN2CCC(C2=N1)C1=CC=CC=C1 Chemical compound CCC(=O)C1=CN2CCC(C2=N1)C1=CC=CC=C1 QRRBMFKBYJOWCZ-UHFFFAOYSA-N 0.000 claims 1
- AGSMIAAEYRCJOK-UHFFFAOYSA-N CCC(=O)C1=NN2C(CCC2=C1)C1=CC=CC=C1 Chemical compound CCC(=O)C1=NN2C(CCC2=C1)C1=CC=CC=C1 AGSMIAAEYRCJOK-UHFFFAOYSA-N 0.000 claims 1
- CACYSZKERVAHES-GFCCVEGCSA-N CCC(=O)C1=NN2CC[C@@H](C2=C1)C1=CC=CC=C1 Chemical compound CCC(=O)C1=NN2CC[C@@H](C2=C1)C1=CC=CC=C1 CACYSZKERVAHES-GFCCVEGCSA-N 0.000 claims 1
- CACYSZKERVAHES-LBPRGKRZSA-N CCC(=O)C1=NN2CC[C@H](C2=C1)C1=CC=CC=C1 Chemical compound CCC(=O)C1=NN2CC[C@H](C2=C1)C1=CC=CC=C1 CACYSZKERVAHES-LBPRGKRZSA-N 0.000 claims 1
- VCCSKRSVEIVDEZ-NSHDSACASA-N CCC(=O)C1=NN2[C@@H](CCC2=N1)C1=C(Cl)C=CC=C1 Chemical compound CCC(=O)C1=NN2[C@@H](CCC2=N1)C1=C(Cl)C=CC=C1 VCCSKRSVEIVDEZ-NSHDSACASA-N 0.000 claims 1
- XWXHREDCBIXXKX-UHFFFAOYSA-N COCC(C)(C)C(=O)c1nc2C(F)CC(c3ccccc3)n2n1 Chemical compound COCC(C)(C)C(=O)c1nc2C(F)CC(c3ccccc3)n2n1 XWXHREDCBIXXKX-UHFFFAOYSA-N 0.000 claims 1
- GAQSYSQXWLHJRU-STQMWFEESA-N CO[C@H]1C[C@H](N2N=C(N=C12)C(=O)C1CC1)C1=CC=CC=C1 Chemical compound CO[C@H]1C[C@H](N2N=C(N=C12)C(=O)C1CC1)C1=CC=CC=C1 GAQSYSQXWLHJRU-STQMWFEESA-N 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- WCIMAPFKNYRSNQ-LBPRGKRZSA-N ClC1=C(C=CC=C1)[C@@H]1CCC2=NC(=NN12)C(=O)C1CC1 Chemical compound ClC1=C(C=CC=C1)[C@@H]1CCC2=NC(=NN12)C(=O)C1CC1 WCIMAPFKNYRSNQ-LBPRGKRZSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- UUKABJSQKLKQPC-UHFFFAOYSA-N FC(CC(=O)C=1N=C2N(N=1)C(CC2F)C1=CC=CC=C1)(F)F Chemical compound FC(CC(=O)C=1N=C2N(N=1)C(CC2F)C1=CC=CC=C1)(F)F UUKABJSQKLKQPC-UHFFFAOYSA-N 0.000 claims 1
- FWMNSADKMMIUCS-UHFFFAOYSA-N FC1CC(N2N=C(N=C21)C(=O)C1C(C1)F)C1=CC=CC=C1 Chemical compound FC1CC(N2N=C(N=C21)C(=O)C1C(C1)F)C1=CC=CC=C1 FWMNSADKMMIUCS-UHFFFAOYSA-N 0.000 claims 1
- UCXDFPTUDIFBRI-UHFFFAOYSA-N FC1CC(N2N=C(N=C21)C(C(C#N)(C)C)=O)C1=CC=CC=C1 Chemical compound FC1CC(N2N=C(N=C21)C(C(C#N)(C)C)=O)C1=CC=CC=C1 UCXDFPTUDIFBRI-UHFFFAOYSA-N 0.000 claims 1
- CWYDYRVJFUPUBS-UHFFFAOYSA-N FC1CC(N2N=C(N=C21)C(C(C)C)=O)C1=CC=CC=C1 Chemical compound FC1CC(N2N=C(N=C21)C(C(C)C)=O)C1=CC=CC=C1 CWYDYRVJFUPUBS-UHFFFAOYSA-N 0.000 claims 1
- BUBIYRFXUZVIIH-UHFFFAOYSA-N FC1CC=2N(N=C(N=2)C(CC)=O)C1C1=CC=CC=C1 Chemical compound FC1CC=2N(N=C(N=2)C(CC)=O)C1C1=CC=CC=C1 BUBIYRFXUZVIIH-UHFFFAOYSA-N 0.000 claims 1
- KCBMPSFKYINJNM-IUCAKERBSA-N F[C@H]1C[C@@H](C2CC2)N2N=C(N=C12)C(=O)C1CC1 Chemical compound F[C@H]1C[C@@H](C2CC2)N2N=C(N=C12)C(=O)C1CC1 KCBMPSFKYINJNM-IUCAKERBSA-N 0.000 claims 1
- QAWQWMLTJDTQKR-RYUDHWBXSA-N F[C@H]1C[C@H](N2N=C(N=C12)C(=O)C1(CC1)C#N)C1=CC=CC=C1 Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)C(=O)C1(CC1)C#N)C1=CC=CC=C1 QAWQWMLTJDTQKR-RYUDHWBXSA-N 0.000 claims 1
- DUECLJOPMDGAGH-STQMWFEESA-N F[C@H]1C[C@H](N2N=C(N=C12)C(=O)C1CC1)C1=C(C=CC=C1)C#N Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)C(=O)C1CC1)C1=C(C=CC=C1)C#N DUECLJOPMDGAGH-STQMWFEESA-N 0.000 claims 1
- GJYUASQMOUKESY-SPOOISQMSA-N F[C@H]1C[C@H](N2N=C(N=C12)C(=O)C1CC11CC1)C1=CC=CC=C1 Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)C(=O)C1CC11CC1)C1=CC=CC=C1 GJYUASQMOUKESY-SPOOISQMSA-N 0.000 claims 1
- WECQKSNRWLFCOH-TTZKSVMKSA-N F[C@H]1C[C@H](N2N=C(N=C12)C(=O)C1CC11CCC1)C1=CC=CC=C1 Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)C(=O)C1CC11CCC1)C1=CC=CC=C1 WECQKSNRWLFCOH-TTZKSVMKSA-N 0.000 claims 1
- NYCYJFQDSUGKHT-TYUFSLCMSA-N F[C@H]1C[C@H](N2N=C(N=C12)C(=O)C1CC1C#N)C1=CC=CC=C1 Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)C(=O)C1CC1C#N)C1=CC=CC=C1 NYCYJFQDSUGKHT-TYUFSLCMSA-N 0.000 claims 1
- ADBUKDYDZJSPOU-KBPBESRZSA-N F[C@H]1C[C@H](N2N=C(N=C12)C(=O)C1CC2(CC2)C1)C1=CC=CC=C1 Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)C(=O)C1CC2(CC2)C1)C1=CC=CC=C1 ADBUKDYDZJSPOU-KBPBESRZSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- KEIDENYTGJNIMO-UHFFFAOYSA-N O=C(C1=NN2C(CCC2=N1)C1=CC=CC=C1)C1(CN2C=CC=N2)CC1 Chemical compound O=C(C1=NN2C(CCC2=N1)C1=CC=CC=C1)C1(CN2C=CC=N2)CC1 KEIDENYTGJNIMO-UHFFFAOYSA-N 0.000 claims 1
- HAMZRZRYHAYBEL-NWDGAFQWSA-N O[C@@H]1C[C@H](N2N=C(N=C12)C(=O)C1CC1)C1=CC=CC=C1 Chemical compound O[C@@H]1C[C@H](N2N=C(N=C12)C(=O)C1CC1)C1=CC=CC=C1 HAMZRZRYHAYBEL-NWDGAFQWSA-N 0.000 claims 1
- HAMZRZRYHAYBEL-RYUDHWBXSA-N O[C@H]1C[C@H](N2N=C(N=C12)C(=O)C1CC1)C1=CC=CC=C1 Chemical compound O[C@H]1C[C@H](N2N=C(N=C12)C(=O)C1CC1)C1=CC=CC=C1 HAMZRZRYHAYBEL-RYUDHWBXSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010053879 Sepsis syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010048327 Supranuclear palsy Diseases 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 230000003589 nefrotoxic effect Effects 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 231100000381 nephrotoxic Toxicity 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000004738 parenchymal cell Anatomy 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 201000002241 progressive bulbar palsy Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000008752 progressive muscular atrophy Diseases 0.000 claims 1
- 201000000196 pseudobulbar palsy Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023061174A JP7734163B2 (ja) | 2017-07-14 | 2023-04-05 | 二環式ケトン化合物及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532767P | 2017-07-14 | 2017-07-14 | |
| US62/532,767 | 2017-07-14 | ||
| PCT/EP2018/068998 WO2019012063A1 (en) | 2017-07-14 | 2018-07-12 | BICYCLIC KETONIC COMPOUNDS AND METHODS OF USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023061174A Division JP7734163B2 (ja) | 2017-07-14 | 2023-04-05 | 二環式ケトン化合物及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526549A JP2020526549A (ja) | 2020-08-31 |
| JP2020526549A5 true JP2020526549A5 (enExample) | 2021-08-19 |
| JP7258843B2 JP7258843B2 (ja) | 2023-04-17 |
Family
ID=62916677
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501256A Active JP7258843B2 (ja) | 2017-07-14 | 2018-07-12 | 二環式ケトン化合物及びその使用方法 |
| JP2023061174A Active JP7734163B2 (ja) | 2017-07-14 | 2023-04-05 | 二環式ケトン化合物及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023061174A Active JP7734163B2 (ja) | 2017-07-14 | 2023-04-05 | 二環式ケトン化合物及びその使用方法 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US11098058B2 (enExample) |
| EP (2) | EP3652178B1 (enExample) |
| JP (2) | JP7258843B2 (enExample) |
| KR (2) | KR102664604B1 (enExample) |
| CN (2) | CN119613408A (enExample) |
| AR (1) | AR112274A1 (enExample) |
| AU (3) | AU2018300043B2 (enExample) |
| BR (1) | BR112020000771A2 (enExample) |
| CA (2) | CA3185865A1 (enExample) |
| CL (1) | CL2020000101A1 (enExample) |
| CO (1) | CO2020000134A2 (enExample) |
| CR (1) | CR20200002A (enExample) |
| DK (1) | DK3652178T3 (enExample) |
| ES (1) | ES2973661T3 (enExample) |
| FI (1) | FI3652178T3 (enExample) |
| HR (1) | HRP20240354T1 (enExample) |
| HU (1) | HUE065793T2 (enExample) |
| IL (2) | IL294961A (enExample) |
| LT (1) | LT3652178T (enExample) |
| MA (1) | MA49560B1 (enExample) |
| PE (1) | PE20200793A1 (enExample) |
| PH (1) | PH12020500105A1 (enExample) |
| PL (1) | PL3652178T3 (enExample) |
| PT (1) | PT3652178T (enExample) |
| RS (1) | RS65308B1 (enExample) |
| SG (1) | SG11202000333UA (enExample) |
| SI (1) | SI3652178T1 (enExample) |
| TW (1) | TWI805595B (enExample) |
| UA (1) | UA125448C2 (enExample) |
| WO (1) | WO2019012063A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11071721B2 (en) | 2016-12-02 | 2021-07-27 | Genentech, Inc. | Bicyclic amide compounds and methods of use thereof |
| CN119613408A (zh) | 2017-07-14 | 2025-03-14 | 豪夫迈·罗氏有限公司 | 二环酮化合物及其使用方法 |
| MX2020003451A (es) | 2017-10-31 | 2020-08-03 | Hoffmann La Roche | Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos. |
| CN113302193B (zh) * | 2019-01-11 | 2026-05-29 | 豪夫迈·罗氏有限公司 | 双环吡咯并三唑酮化合物及其使用方法 |
| WO2021198981A1 (en) | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Antiviral compounds and uses thereof |
| JP7626347B2 (ja) | 2020-04-27 | 2025-02-04 | オートタック インコーポレーテッド | Ｕｂｒボックスドメインリガンドとしての化合物 |
| CA3214802A1 (en) | 2021-04-02 | 2022-10-06 | Genentech, Inc. | Processes for making bicyclic ketone compounds |
| WO2023039795A1 (zh) * | 2021-09-16 | 2023-03-23 | 维泰瑞隆（北京）生物科技有限公司 | Rip1激酶抑制剂及其用途 |
| WO2023225041A1 (en) | 2022-05-19 | 2023-11-23 | Merck Sharp & Dohme Llc | Ripk1 inhibitors and methods of use |
| AU2024312554A1 (en) * | 2023-06-19 | 2025-12-18 | F. Hoffmann-La Roche Ag | Process for the preparation of a chiral pyrrolo triazole alcohol |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1620508A1 (de) | 1965-07-23 | 1969-09-18 | Thomae Gmbh Dr K | Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3948903A (en) | 1972-12-15 | 1976-04-06 | Parke, Davis & Company | Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| GB8610530D0 (en) | 1986-04-30 | 1986-06-04 | Fbc Ltd | Herbicides |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| AU677216B2 (en) | 1992-07-27 | 1997-04-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Targeting of liposomes to the blood-brain barrier |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| EP1007042A4 (en) | 1997-06-13 | 2001-07-04 | Sugen Inc | NEW HETEROCYCLIC COMPOUNDS FOR MODULATING THE PROTEIN-TYROSIN-ENZYME-RELATED CELLULAR SIGNAL TRANSDUCTION |
| JP2004502642A (ja) * | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| CA2450073C (en) | 2001-07-25 | 2017-08-29 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| PL382706A1 (pl) | 2002-08-26 | 2007-11-26 | Takeda Pharmaceutical Company Limited | Związek modulujący receptor wapnia i jego zastosowanie |
| JP4995423B2 (ja) | 2002-12-03 | 2012-08-08 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア |
| ATE410161T1 (de) | 2003-05-02 | 2008-10-15 | Elan Pharm Inc | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen |
| WO2005025511A2 (en) | 2003-09-10 | 2005-03-24 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
| JP2008539220A (ja) | 2005-04-26 | 2008-11-13 | ファイザー・リミテッド | バソプレシンアンタゴニストとしてのトリアゾール誘導体 |
| EP2083009A1 (de) | 2008-01-22 | 2009-07-29 | Grünenthal GmbH | Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| CN101824036A (zh) | 2009-03-05 | 2010-09-08 | 上海恒瑞医药有限公司 | 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用 |
| UY32776A (es) | 2009-07-09 | 2011-02-28 | Irm Llc | Compuestos de imidazopirazinas sustituidas para el tratamiento de enfermedades parasitarias,composiciones farmacéuticas que los contienen y aplicación. |
| CA2852964A1 (en) | 2011-11-03 | 2013-05-10 | F. Hoffmann-La Roche Ag | Bicyclic piperazine compounds |
| JP6267193B2 (ja) | 2012-05-22 | 2018-01-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 置換ジピリジルアミン類及びそれらの使用 |
| MX2015009270A (es) | 2013-01-18 | 2015-10-30 | Hoffmann La Roche | Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk). |
| TWI648274B (zh) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| TWI710558B (zh) | 2013-05-01 | 2020-11-21 | 瑞士商赫孚孟拉羅股份公司 | 二雜芳基化合物及其用途 |
| RU2015147601A (ru) | 2013-05-01 | 2017-06-05 | Ф. Хоффманн-Ля Рош Аг | С-связанные гетероциклоалкилзамещенные пиримидины и их применения |
| AU2014287471C1 (en) | 2013-07-10 | 2019-11-28 | Vertex Pharmaceuticals Incorporated | Fused piperidine amides as modulators of ion channels |
| MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| CR20160418A (es) | 2014-03-26 | 2016-11-07 | Hoffmann La Roche | Nuevos compuestos biciclicos de 7 eslabones |
| RU2017109122A (ru) | 2014-08-21 | 2018-09-21 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы |
| WO2016128908A1 (en) * | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| JP6701225B2 (ja) | 2015-03-09 | 2020-05-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 三環式ｄｌｋ阻害剤及びその使用 |
| RU2716136C2 (ru) * | 2015-07-02 | 2020-03-06 | Ф. Хоффманн-Ля Рош Аг | Бициклические лактамы и способы их применения |
| CN108602809B (zh) | 2015-12-04 | 2022-09-30 | 戴纳立制药公司 | 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂 |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| US9815850B2 (en) | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| US11071721B2 (en) | 2016-12-02 | 2021-07-27 | Genentech, Inc. | Bicyclic amide compounds and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| CN110169087B (zh) | 2017-01-05 | 2021-04-20 | 微软技术许可有限责任公司 | 重定向音频输出 |
| CN119613408A (zh) | 2017-07-14 | 2025-03-14 | 豪夫迈·罗氏有限公司 | 二环酮化合物及其使用方法 |
| WO2019072942A1 (en) | 2017-10-11 | 2019-04-18 | F. Hoffmann-La Roche Ag | BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1 |
| MX2020003451A (es) | 2017-10-31 | 2020-08-03 | Hoffmann La Roche | Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos. |
-
2018
- 2018-07-12 CN CN202411725301.0A patent/CN119613408A/zh active Pending
- 2018-07-12 UA UAA202000831A patent/UA125448C2/uk unknown
- 2018-07-12 FI FIEP18740815.8T patent/FI3652178T3/fi active
- 2018-07-12 SG SG11202000333UA patent/SG11202000333UA/en unknown
- 2018-07-12 WO PCT/EP2018/068998 patent/WO2019012063A1/en not_active Ceased
- 2018-07-12 LT LTEPPCT/EP2018/068998T patent/LT3652178T/lt unknown
- 2018-07-12 KR KR1020207004030A patent/KR102664604B1/ko active Active
- 2018-07-12 PT PT187408158T patent/PT3652178T/pt unknown
- 2018-07-12 CA CA3185865A patent/CA3185865A1/en active Pending
- 2018-07-12 HU HUE18740815A patent/HUE065793T2/hu unknown
- 2018-07-12 IL IL294961A patent/IL294961A/en unknown
- 2018-07-12 HR HRP20240354TT patent/HRP20240354T1/hr unknown
- 2018-07-12 ES ES18740815T patent/ES2973661T3/es active Active
- 2018-07-12 EP EP18740815.8A patent/EP3652178B1/en active Active
- 2018-07-12 BR BR112020000771-4A patent/BR112020000771A2/pt active Search and Examination
- 2018-07-12 RS RS20240314A patent/RS65308B1/sr unknown
- 2018-07-12 CN CN201880046714.2A patent/CN110914271B/zh active Active
- 2018-07-12 US US16/034,207 patent/US11098058B2/en active Active
- 2018-07-12 IL IL271981A patent/IL271981B/en unknown
- 2018-07-12 AU AU2018300043A patent/AU2018300043B2/en active Active
- 2018-07-12 DK DK18740815.8T patent/DK3652178T3/da active
- 2018-07-12 EP EP24152498.2A patent/EP4397309B1/en active Active
- 2018-07-12 PE PE2020000027A patent/PE20200793A1/es unknown
- 2018-07-12 AR ARP180101941 patent/AR112274A1/es active IP Right Grant
- 2018-07-12 PL PL18740815.8T patent/PL3652178T3/pl unknown
- 2018-07-12 KR KR1020247014915A patent/KR20240065201A/ko active Pending
- 2018-07-12 TW TW107124048A patent/TWI805595B/zh active
- 2018-07-12 CR CR20200002A patent/CR20200002A/es unknown
- 2018-07-12 CA CA3067944A patent/CA3067944C/en active Active
- 2018-07-12 SI SI201831080T patent/SI3652178T1/sl unknown
- 2018-07-12 JP JP2020501256A patent/JP7258843B2/ja active Active
- 2018-07-12 MA MA49560A patent/MA49560B1/fr unknown
-
2020
- 2020-01-08 CO CONC2020/0000134A patent/CO2020000134A2/es unknown
- 2020-01-13 CL CL2020000101A patent/CL2020000101A1/es unknown
- 2020-01-14 PH PH12020500105A patent/PH12020500105A1/en unknown
-
2021
- 2021-01-12 US US17/147,449 patent/US11834461B2/en active Active
- 2021-06-26 AU AU2021204369A patent/AU2021204369A1/en not_active Abandoned
-
2023
- 2023-04-05 JP JP2023061174A patent/JP7734163B2/ja active Active
- 2023-05-25 AU AU2023203292A patent/AU2023203292B2/en active Active
- 2023-11-21 US US18/516,014 patent/US20240300974A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7398391B2 (ja) | Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物 | |
| JP2024532734A (ja) | 複素環式化合物及び使用方法 | |
| AU2023356614A1 (en) | Heterocyclic inhibitors of kras g12c mutant proteins and uses thereof | |
| CN107531690B (zh) | 用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物 | |
| JP7734163B2 (ja) | 二環式ケトン化合物及びその使用方法 | |
| JP2013523884A5 (enExample) | ||
| JP2019516759A (ja) | がんの処置のためのピラゾロピリジン誘導体 | |
| JP2020515603A (ja) | Ｈｐｋ１阻害剤としてのイソキノリン | |
| TW201514145A (zh) | 作為ｂｔｋ抑制劑的初級甲醯胺 | |
| JP7362600B2 (ja) | Ｒｉｐ１キナーゼ阻害剤として使用するための二環式化合物 | |
| EP3218376A1 (en) | Bromodomain inhibitors and uses thereof | |
| CN107108512A (zh) | 治疗性化合物及其用途 | |
| JP2017511365A (ja) | 複素環キナーゼ阻害薬 | |
| JP2020536915A5 (enExample) | ||
| KR20250130621A (ko) | 치환된 디하이드로피롤로[3,4-d]피리미딘 화합물 및 의학적 병태 치료에서의 이의 용도 | |
| JP2023537055A (ja) | Ａｔｒ阻害剤およびその使用 | |
| KR102598203B1 (ko) | 델타-5 불포화효소 억제제로서의 헤테로시클릭 화합물 및 사용 방법 | |
| JP2013518823A5 (enExample) | ||
| JP2023520647A5 (enExample) | ||
| JP2009500366A5 (enExample) | ||
| JP2022516651A5 (enExample) | ||
| JP2026513962A (ja) | 炎症性疾患の処置のためのチロシンキナーゼ２（ＴＹＫ２）阻害剤としての１Ｈ－ピロロ［２，３－ｂ］ピリジン－４－イル］－２－オキソピロリジン－３－カルボニトリル誘導体 | |
| JP2023538097A (ja) | ピリミジノン化合物およびその使用 | |
| NZ760749B2 (en) | Bicyclic ketone compounds and methods of use thereof | |
| HK40099028A (en) | Oxazepine compounds and uses thereof in the treatment of cancer |